News | January 09, 2015

FDA Clears Version 1.2 of Dune Medical’s MarginProbe

Real-time breast cancer-detection device update offers brighter screen, reduced size and emphasized alerts

Dune Medical Devices, MarginProbe, version 1.2, FDA, breast cancer detection

Image courtesy of Dune Medical Devices

January 9, 2015 — Dune Medical Devices announced U.S. Food and Drug Administration (FDA) approval of an updated version of its flagship product, MarginProbe, a medical device that enables real-time detection of cancer at the surface of excised tissue specimens during breast-conserving cancer surgery.

Surgeon feedback, innovative design ideas and superior miniaturization engineering were the driving forces behind the development of MarginProbe 1.2. This new version, which utilizes the same FDA-approved diagnostic technology as version 1.1, is focused on providing superior functionality, portability and overall ease of use.

Feature enhancements for MarginProbe 1.2 include:

  • Reduced size & weight: The new unit is in tabletop form (29 x 43 x 38 cm in size) and weighs 35 lbs. making it 75-percent lighter and much easier to handle.
  • Brighter screen: The screen’s brightness has been enhanced to provide surgeons a clearer screen image.
  • Wider viewing angle: With MarginProbe 1.2, surgeons will have the ability to clearly view the screen from anywhere in the operating room without encountering a glare, pixelation or a blind spot.
  • Improved on-screen notices: Ensuring key alerts are easier to notice in the OR ambience.
  • Startup time cut in half: The startup time for MarginProbe 1.2 is reduced from approximately three minutes to 90 seconds.
  • Improved service time: Due to its new reduced size, technicians are able to provide faster service, reducing down time in case service is needed.

For more information: www.dunemedical.com

Related Content

Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RSNA Study Shows Real-Time Indicator Improves Mammographic Compression
News | Mammography | December 12, 2018
Sigmascreening recently announced that more than 100,000 women have had mammography exams with the Sensitive Sigma...
Massachusetts Superior Court Grants Hologic Preliminary Injunction in Trade Secrets Lawsuits
News | Mammography | December 12, 2018
December 12, 2018 — A Massachusetts Superior Court granted a preliminary injunction in lawsuits by Hologic against Ch
Videos | Mammography | December 10, 2018
Stamatia Destounis, M.D., FACR, associate professor, University of Rochester School of Medicine, and attending radiol
FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...
Fujifilm Collaborates With Lunit on AI Pilot Project
News | Artificial Intelligence | December 05, 2018
Fujifilm Medical Systems USA Inc. announced a joint collaboration with Korean-based medical artificial intelligence (AI...
ScreenPoint Medical and Volpara Partner to Bring AI to Breast Imaging Clinics
News | Computer-Aided Detection Software | December 04, 2018
ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will...
GE Healthcare Introduces Invenia ABUS 2.0
Technology | Ultrasound Women's Health | December 03, 2018
GE Healthcare recently launched the Invenia automated breast ultrasound (ABUS) 2.0 system in the United States. This...
Snoring Poses Greater Cardiac Risk to Women
News | Women's Health | November 29, 2018
Obstructive sleep apnea (OSA) and snoring may lead to earlier impairment of cardiac function in women than in men,...
ScreenPoint Medical Receives FDA Clearance for Transpara Mammography AI Solution
Technology | Computer-Aided Detection Software | November 28, 2018
November 28, 2018 — ScreenPoint Medical announced it has received 510(k) clearance from the U.S.